PUBLICATIONS

Books and monographs (reviews) published:

Lossos, I; Rosenblatt, R. Rituximab for Treatment of Chemo-Immunotherapy Naïve Marginal Zone Lymphoma GLAL-2007-0234. Leukemia and Lymphoma. Accepted. 2007

Zhang, Y; Nechushtan, H; Chan, Andrew; Podack, E; Levy, R; Rosenblatt, J. Immune effects of B cell depletion on the T cell response: Analysis in the human CD20 transgenic mouse model, Rituximab-mediated Molecular Signaling and Interaction with Chemotherapeutic Drugs, 2007.


Calfa, C; Rosenblatt, J; Cho, H; Webster, K; Shin, S. Antibodies and Antibody-fusion Proteins as Anti-angiogenic, Anti-tumor Agents. Cancer Chemotherapy & Biological Response Modifiers Annual 23. 1(2) 159-173. 2006.


Rosenblatt, JD. A Human Non-HIV retroviral infections; Editorial Comment in Infections in Medicine, 1994, 11:547.


Rosenblatt JD: Human Retrovirology: HTLV. In Cancer Cells, Blattner W


Juried or refereed journal articles and exhibitions:

Oizumi, S; Deyev, V; Yamazaki, K; Schreiber, T; Strbo, N.; Rosenblatt, J; Podack, E.R. Surmounting tumor induced immune suppression by frequent vaccination or immunization in the absence of B cells. Cancer Research. 2008 May;31(4):394-401.


Raez LE; Langmuir V; Papadopoulos K; Ricart A; Tolba K; Rocha-Lima C; Schlesselman S; Kroll S; Colowick A; Rosenblatt J; Lampidis T. Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas. J of Thor Onc Oct 2006; vol 1: 8, 905a.


Chen Y, Pandya K, Keng PP, Feins R, Raubertas R, Smudzin T, Rosenblatt JD, Okunieff P. Schedule-dependent pulsed paclitaxel radiosensitization for


Watanabe CT, Rosenblatt JD, Bakker A, Morgan JP, Luo J, Chun S, Black


Danon YL, Rosenblatt JD, Ejima E. Molecular characterization of HTLV-I


Rosenblatt JD, Giorgi JV, Golde DW, Ezra JB, Wu A, Winberg CD, Glaspy J,


Other works accepted for publication:

Funded Research & Other Support Performed (include all grants received in the last five years, identifying the principal investigator):

**ACTIVE:**

The Leukemia & Lymphoma Society, Society (PI: J. Rosenblatt), Translational Research Anti-CD20 Antibody-NKG2D Ligand Fusion Proteins for Lymphoma Therapy, 10/1/07-9/30/11.

Bank Head Coley, (PI: W. Harrington CoPI: J. Rosenblatt), Pathogenesis and Therapy of Viral Lymphomas. (Project 3).

Institutional Research Grant (PI: J. Rosenblatt), Integrated Training in Cancer Research at UM/Sylvester, American Cancer Society, 1/1/07-12/31/09.


5-R01-CA-87978-06 (P.I. Joseph Rosenblatt) NIH/NCI Title: HSV Amplicon Activation of Innate and Adaptive Immunity. 5/1/00 – 5/31/09

**COMPLETED:**

R01A1041957-01, (P.I. Joseph D. Rosenblatt), NIH, Title: Inhibition of HIV-1 Using a Mutant tRNA Primer, A Novel Gene Therapy Strategy for HIV-1 Infection. 7/01/97-12/31/01. (Completed)

5-R01-CA74273-01A2, (P.I. Joseph D. Rosenblatt) NIH/NCI, Title: Antibody Fusion Proteins for the Therapy of Cancer. 1/15/99-12/31/03. (Completed)

3 R01CA74273-01A281, (P.I. Joseph D. Rosenblatt) NIH/NCI, Title: Antibody Fusion Proteins for the therapy of Cancer. Supplemental award for study of B-cell deficient mouse model as supplemental model to above R01 CA 74273. 01/15/99-12/31/01. (Completed)

R01 CA87978-01 (P.I. Joseph D. Rosenblatt) NIH/NCI, Title: Chemokine Enhanced Immune Therapy of Lymphoma, Project Goal is Use of HSV
Amplicon Vectors Encoding Chemokines/Costimulatory Ligands as a Gene Therapy Strategy for Lymphoma.  
5/1/00-4/30/03. (Completed) 

2 RO1 AR 40325-05, Co-investigator, J. Rosenblatt (P.I. Randy N. Rosier, M.D., Ph.D.) NIH, Title: Autocrine and I onic Regulation of Chondrocyte Phenotype, 09/30/97-08/30/02. (Completed) 

1R01 A149057-01-Co-Investigator: Joseph Rosenblatt, (P.I. Vicente Planelles, PhD), NIH, Title: Induction of Apoptosis by HIV-1 vpr. 09/15/00-08/31/05 (Completed) 

LSA #6671-01 (P.I. Joseph Rosenblatt, MD) Leukemia Society of America, Translational Research Award, Title: Chemokine Augmented Immune Therapy of Lymphoma. 07/01/00 - 6/30/03 (Completed) 

ACS EDT # 90: Research Award, Robert Seeger and Joseph Rosenblatt, Co-Principal Investigators, Enhanced Immunogenicity of Neuroblastoma Cells by Genetic Engineering, 01/01/95-12/31/97 (Completed) 

NCI-1RO1CA052410: Rosenblatt, JD, PI. Pathogenesis of HTLV-I Associated Myelopathy, 7/1/90-6/30/93 (Completed) 

NCI-1R01CA053632: Rosenblatt JD, PI. Regulation of Gene Expression in HTLV Type I/II, 9/20/90-8/31/95. (Completed) 

Applied Immune Sciences, Unrestricted grant for investigation of tRNA vectors, completed, 1995-1996. (Completed) 


CA PO1 CA59326: NIH, NCI Joseph Rosenblatt, Co-PI (PI: James Economou) Gene Therapy for Cancer Program Project: Enhanced Immunogenicity of Neuroblastoma Cells by Genetic Engineering, 09/30/92-12/31/98 (Completed) 

University of Rochester Cancer Center Discovery Fund: Reversal of Tolerance and Eradication of the Existing Lymphoma. Seed funding for Dr. Khaled Tolba, Fellow in Dr. Rosenblatt's laboratory, 1/01/98-12/31/98 (Completed) 

Wilmot Cancer Research Fellowship-Mentor for Corliss Newman, M.D.: Postdoctoral Fellow, Dr. Rosenblatt's Laboratory, 7/01/98-6/30/99 (Completed)
New York State Breast Cancer Program-Mentor for Shannon Hilchey, Ph.D., Postdoctoral Fellow, Dr. Rosenblatt's Laboratory, A Novel Model for Xenograft-Targeted Immunotherapy of Breast Cancer, 11/02/98-11/01/00. (Completed)

**Participation in Training/Institutional Grants:**


Fellowship Grant - Sanofi-Synthelabo (PI: J. Rosenblatt) 5/1/04 – 4/30/06.

LSA #2011-99 (PI: Jane Liesveld, M.D. B J. Rosenblatt Sponsor Only), Leukemia Society of America Cancer Development Award, Leukemia Society of America Scholar. 9/01/98-8/31/03

T32 CA09363-20 (PI: Russell Hilf, M.D. B J. Rosenblatt as Mentor for Qiang Lou, Ph.D. Postdoctoral Fellow, Dr. Rosenblatt's Laboratory, NIH, University of Rochester Cancer Center Training Grant. 9/15/97-6/30/02

Wilmot Cancer Research Fellowship - Funding for Khaled Tolba, M.D. Fellow in Dr. Rosenblatt's Laboratory, Title: HSV Amplicon mediated gene therapy of hematologic malignancies. 7/01/99-6/30/02

T32 HLO7152-25: (PI: Charles Francis), Co-Investigator: J. Rosenblatt, Graduate training in Hematology Research, 07/01/96-06/30/01

UO1 A127658-15: (PI: Richard Reichman), Co-Investigator: J. Rosenblatt, Adult AIDS Clinical Trials Unit, 01/01/00-12/31/04

CA11198-28 NIH: (PI: Richard Borch) Joseph Rosenblatt Associate Director for Clinical Research of the Cancer Center. Core Cancer Center Support Grant, 05/18/95-04/30/98

**Clinical Trials:**

Seattle Genetics, Inc., Joseph Rosenblatt, Investigator. **Title:** A Pilot Study of Initial Therapy for Advanced and Poor Prognosis Stage IIB Hodgkin’s disease with anti-CD30 Monoclonal Antibody (SGN-30) in combination with ABVD, 2004

Chiron Corporation, Joseph Rosenblatt, Investigator. **Title:** An Open Label Phase II/III Study of Rituximab in Combination with Recombinant Human IL-
2 (IL-2) for Relapsed Low-grade or Follicular Non-Hodgkins Lymphoma in subjects who have previously failed Rituximab 1/4/02 – 12/31/06

Chiron Corporation, Joseph Rosenblatt, Investigator. **Title:** An Open-Labeled, Phase II Study of Rituximab in Combination with Recombinant Human IL-2 for Relapsed or Refractory Non-Hodgkin’s Lymphoma of Intermediate or High-Grade Histology. 1/17/03 – 1/17/07

Seattle Genetics, Joseph Rosenblatt, Investigator. **Title:** A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma. 12/9/03 – 12/9/07

Seattle Genetics, Joseph Rosenblatt, Investigator. **Title:** An Extension Study for Patients with Hodgkin’s Disease or Non-Hodgkins Lymphoma Previously treated with SGN-30 (anti-CD-30 mAb). 4/28/04 – 12/31/06

Seattle Genetics, Joseph Rosenblatt, Investigator. **Title:** A Phase I, Multidose Study of SGN-400 (anti-HUCD40MAB) in Patients with Non-Hodgkin’s Lymphoma. 10/12/04 – 12/31/06

Chiron Corporation Trial Agreement B Joseph Rosenblatt, Investigator, **Title:** Phase II Study of IDEC and IL-2 in pts with Low-Grade of Follicular B-cell Lymphoma, Investigator Initiated, 01/15/98-12/31/01

Genentech, Inc Trial Agreement B Joseph Rosenblatt, Investigator, **Title:** Phase II Study of IDEC and IL-2 in Patients with Low-grade of Follicular B-Cell Lymphoma, Investigator Initiated, 1/15/98-12/31/99

Janssen Pharmaceuticals Trial Agreement B Joseph Rosenblatt, Investigator, **Title:** Phase II Trial of KW2189 in the Treatment of Patients with Non-Small Cell Lung Cancer, 01/01/97-12/31/97

Maxim Pharmaceuticals Trial Agreement-Joseph Rosenblatt, Investigator, **Title:** Study to Evaluate the Safety & Efficiency of Combined Immunotherapy w/Subcutaneous Interleukin-2, and Histamine Dihydrochloride, 03/15/99-06/30/02

Transgene, Inc. Trial Agreement B Joseph Rosenblatt, Investigator, **Title:** Phase I Trial of Immunotherapy with Adenovirus-Interferon (TG1041) in Patients with malignant melanoma, Investigator Initiated, 03/15/99-06/30/02

SmithKline Beecham B Joseph Rosenblatt, Investigator, **Title:** Study Comparing Efficacy and Safety of Kytril Tablets w/Placebo, in the Prevention
of Nausea and Vomiting During the Days Following Administration.
04/15/99-04/14/00

Janssen Pharmaceuticals Joseph Rosenblatt, Investigator, Title: Phase I Study to Determine the Biological Endpoints of Up to 21 Day Dosing of Farnesyl transferase Inhibitor, Investigator Initiated, 06/01/98-12/31/01

Prologue Research International Joseph Rosenblatt, Investigator, Title: A Compassionate Use Study of Oxaliplatin for Previously Treated Colorectal Patients, 09/14/00-09/15/01

Janssen Pharmaceuticals Trial Agreement, Joseph Rosenblatt, Investigator, Title: Phase I/II Pilot Study of KW2189 for Treatment of Pancreatic Carcinoma, 09/15/96-09/14/98

Janssen Pharmaceuticals Trial Agreement, Joseph Rosenblatt, Investigator, Title: Phase I/II Pilot Study of KW2189 for Treatment of Relapsed Gastric CA, 09/01/96-08/31/97

Amgen, Inc. Trial Agreement, Joseph Rosenblatt, Investigator, Title: Randomized Trial of Peripheral Blood Progenitor Cell Mobilization by Recombinant Human SCF and Filgrastim, 11/01/95-10/31/96

Genentech, Inc Trial Agreement, Joseph Rosenblatt, Investigator, Title: A Multicenter, Open-label, Phase III, Randomized Active Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF, 10/01/00-12/31/03

Berlex, Inc Proposal, Joseph Rosenblatt, Investigator, Title: Phase I Trial of Combined Therapy of Campath and IL-2 for the Treatment of Relapsed/Refractory CLL, T-PLL and Cutaneous T-Cell Lymphoma, 3/24/04 – 11/1/06

Seattle Genetics, Joseph Rosenblatt, Investigator: Title: An Extension Study for Patients with Hodgkin’s Disease or Non-Hodgkin’s Lymphoma Previously Treated with SGN-30 (anti-CD-30 mAb), 5/1/04 – 4/30/06